Company: TELO
Filing Date: 2025-11-28
Form Type: PRER14A
Source: 0001493152-25-025406
Chunk: 22

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-28
Form: PRER14A
Chunk 22
---
isable upon FDA acceptance of an Investigational New Drug (IND) application for Telomir-1 at $2.00 per share, for a period of 10 years. At Closing, under the terms of the Merger Agreement, the Warrants will be converted to warrants to purchase Telomir Common Stock at similar terms as the Warrants.

Conditions to the Merger (see page 40)

The obligations to consummate the Merger and the other Contemplated Transactions are subject to the satisfaction or waiver, on or prior to the Effective Time, of the conditions set forth in the section entitled “ The Merger Agreement—Conditions to the Merger” below.

Termination (see page 40)

The Merger Agreement contains certain customary termination rights, including the right of either TELO or TELI to terminate the Merger Agreement if either company’s stockholders fail to adopt and approve the Merger Proposal, if the Closing has not occurred by December 31, 2025, if a governmental entity has issued a final ruling prohibiting the Closing, or by one party upon an uncured breach of the Merger Agreement. For a more complete description of the termination provisions, please see the section titled “ The Merger Agreement—Termination.”

Appraisal Rights and Dissenters’ Rights (see page 41)

Pursuant to Section 607.1302 of the Florida Business Corporation Act, the shareholders of TELO will not be entitled to appraisal rights as a result of the Merger.

Pro Forma Financial Statements of TELO Following the Merger

Please see page 41 of this proxy statement for the pro forma financial statements of TELO following the Merger.

Executive Officers of the Combined Company Following the Merger (see page 35)

Immediately following the Merger, the executive management team of TELO is expected to remain the same as prior to the Merger and be comprised of the following individuals with such additional officers as may be added by the combined company:

| Name         |     | Position          
 with TELO         |
| Erez         
 Aminov       |     | Chief             
 Executive Officer |
| Alan         
 Weichselbaum |     | Chief             
 Financial Officer |

| 10 |

Directors of the Combined Company Following the Merger (see page 36)

Following the Merger, TELO is expected to maintain four of the directors that were in office prior to the Merger, comprised of Matthew Pratt Whalen CPA, Erez Aminov, Edward MacPherson, and